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Abstract: The objective of this research is to generate leads for developing our ultimate
poly-active molecules with utility in central nervous system (CNS) diseases. Indeed, poly-active
molecules capable of mitigating brain free radical damage while enhancing acetylcholine signaling
(via cholinesterase inhibition) are still being sought for combating Alzheimer’s disease (AD).
We differentiate “poly-active” agents from “multi-target” ones by defining them as single
molecular entities designed to target only specific contributory synergistic pharmacologies in
a disease. For instance, in AD, free radicals either initiate or act in synergy with other
pharmacologies, leading to disease worsening. For this preliminary report, a total of 14
(i.e., 4,5-dimethoxy-2-nitrobenzohydrazide plus 1-(1-benzylpiperidin-4-yl)ethan-1-one) derivatives
were synthesized and screened, in silico and in vitro, for their ability to scavenge free radicals and
inhibit acetylcholinesterase (AChE)/butyrylcholinesterase (BuChE) enzymes. Overall, six derivatives
(4a, 4d, 4e, 4f, 4g, 9b) exhibited potent (>30%) antioxidant properties in the oxygen radical absorbance
capacity (ORAC) assay. The antioxidant values were either comparable or more potent than the
comparator molecules (ascorbic acid, resveratrol, and trolox). Only three compounds (4d, 9a, 9c)
yielded modest AChE/BuChE inhibitions (>10%). Please note that a SciFinder substance data base
search confirmed that most of the compounds reported herein are new, except 9a and 9c which are
also commercially available.
Keywords: poly-active; antioxidant; hydrazones; isonipecotates; cholinesterase; in silico

1. Introduction
Disease-modifying, anti-Alzheimer’s disease (AD) molecules continue to elude both big and
small pharma discovery approaches. Part of the problem is that AD pathology is underpinned by
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modify multi-factorial diseases like AD and slow its progression.
1. Introduction
Our initial search for potentially poly-active small (Formular Weight (FW) < 500) molecule leads
anti-Alzheimer’s disease (AD) molecules continue to elude both big and
possessing Disease-modifying,
free radical, acetylcholinesterase
(AChE) suppressive activities has thus far produced
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multi-pronged
attributes,
thatpotentially
is, theirpoly-active
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neurons in AD [13–15]. Enzyme inhibition tests were conducted, both in silico (predictively for AChE
For instance,
while their inhibition improves the acetylcholine (ACh) signaling for memory/cognition,
only) and in vitro (to confirm for AChE/butyrylcholinesterase (BuChE)). Interestingly,
the twocholinesterases
enzymes alsocontinue
contribute
to plaque assembly in AD [12,16].
to be drug design targets in this arena, even though their sole role in AD
remains somewhat unclear. For instance, while their inhibition improves the acetylcholine (ACh)
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signaling for memory/cognition, the two enzymes also contribute to plaque assembly in AD [12,16].
2.1. Synthesis
2. Materials and Methods

Hydrazone
synthesis occurred in two steps (Scheme 1) [6–8]. Step one involved refluxing methyl
2.1. Synthesis
4,5-dimethoxy-2-nitrobenzoate 1 and excess hydrazine monohydrate in absolute ethanol, and afforded
Hydrazone synthesis occurred in two steps (Scheme 1) [6–8]. Step one involved refluxing methyl
intermediate 2 in yields of 60–70%. In step two, intermediate 2 was condensed with a variety of
4,5-dimethoxy-2-nitrobenzoate 1 and excess hydrazine monohydrate in absolute ethanol, and
aromaticafforded
aldehydes
3a–k to2form
arylated
hydrazones
4a–k
as solids 2(Figure
1, 70%-quantitative
intermediate
in yields
of 60–70%.
In step two,
intermediate
was condensed
with a variety yields).
Exploratory
arylated
isonipecotates
9a–c
were
prepared
beginning
with
the
trimethylamine-facilitated
of aromatic aldehydes 3a–k to form arylated hydrazones 4a–k as solids (Figure 1, 70%‐quantitative
yields). Exploratory
arylated
isonipecotates
were(Scheme
prepared 2)
beginning
with the
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of isonipecotate
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[9]. Reaction
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intermediate
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led
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carboxylic
acid
intermediate,
the benzylated intermediate 6 were >90%. Ester hydrolysis, under basic reflux, led to the carboxylic
which was promptly converted to the acyl chloride 7 via the dropwise addition of SOCl2 . Finally, acyl
acid intermediate, which was promptly converted to the acyl chloride 7 via the dropwise addition of
chlorideSOCl
treatment
with appropriate amines 8a–c, in step three (Scheme 2), afforded target products
2. Finally, acyl chloride treatment with appropriate amines 8a–c, in step three (Scheme 2),
9a–c (60–75%
overall
yields). 9a–c (60–75% overall yields).
afforded target products

Scheme 1. Reagents and conditions: (i) NH2NH2, EtOH, 60 °C, 60–70%; (ii) Hydrazide, 2,3-

Scheme 1. Reagents and conditions: (i) NH2 NH2 , EtOH, 60 ◦ C, 60–70%; (ii) Hydrazide,
dihydrobenzofuran-6-carbaldehyde, EtOH, HCl, room temperature, 70%—quantitative.
2,3-dihydrobenzofuran-6-carbaldehyde, EtOH, HCl, room temperature, 70%—quantitative.

Scheme 2. Reactions and conditions: (i) Benzyl chloride, Et3N, toluene, room temperature, > 90%; (iia)
NaOH,
Sci. Pharm. 2018,
86, 2H2O, CH3OH, reflux, not isolated; (iib) CH2Cl2, SOCl2, reflux, not isolated; (iiia) Et3N, NH2-Ar,
dioxane or CH2Cl2, reflux, 60–75%; (iiib) HCl-ether, >80%.
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2.2. Oxygen Radical Absorbance Capacity (ORAC) Assay
We needed to screen our compounds for their direct radical scavenging capabilities in both lipid
and aqueous environments. To that end, we utilized the oxygen radical absorbance capacity (ORAC)
assay, which measures peroxyl radical scavenging via hydrogen atom transfer (HAT) or electron
Scheme
2. Reactions
and conditions:
Benzylchloride,
chloride, EtEt
3N, toluene, room temperature, > 90%; (iia)
Scheme
2. (ET)
Reactions
conditions:
(i)(i)Benzyl
N, toluene,
room
temperature,
90%; (iia)
transfer
to the and
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or pre-formed
radical. Assays
are well
reported
[17,18].>Briefly,
3details
NaOH, H2O, CH3OH, reflux, not isolated; (iib) CH2Cl2, SOCl2, reflux, not isolated; (iiia) Et3N, NH2-Ar,
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known
our assay
and2 Cl
2,2′-azobis(2-amidino-propane)
dihydrochloride
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isolated;
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3 OH, conditions
2 , SOCl2 , reflux, not isolated; (iiia)
dioxane or CH2Cl2, reflux, 60–75%; (iiib) HCl-ether, >80%.
(AAPH)
oxidant or peroxyl radical ROS generator [19–21]. In our hands, 4.19 µ M fluorescein
dioxane
or as
CHthe
2 Cl2 , reflux, 60–75%; (iiib) HCl-ether, >80%.
stock solution was prepared in 75 mM phosphate buffer (pH = 7.4, kept at 4 °C), diluted with the
same buffer to a concentration of 0.0816 µ M, and incubated at 37 °C for 15 min before assaying. A
2.2. Oxygen Radical Absorbance Capacity (ORAC) Assay
fresh 153 mM AAPH solution in the said buffer was prepared, kept on ice, and used for 4 h at the
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in water, and
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our compounds
their10
direct
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in 50
both lipid
mM stock solutions of test compounds in DMSO were prepared, and each was diluted to 80 µ M with
and aqueous environments. To that end, we utilized the oxygen radical absorbance capacity (ORAC)
ethanol. Subsequently, 25 µ L of each diluted stock solution or 25 µ L of ethanol with 0.16% DMSO in
assay, which
measures peroxyl radical scavenging via hydrogen atom transfer (HAT) or electron
case of control (no test or reference compound) was plated with 150 µ L of fluorescein solution, and
transfer25(ET)
to
theabove
existing
or pre-formed
are well
reported fluorescence
[17,18]. Briefly, we
µ L of the
AAPH
solution was radical.
added to Assays
all wellsdetails
except those
for maximum
utilizedcontrol.
knownThus,
conditions
for our assay
and9a–c,
2,20 -azobis(2-amidino-propane)
dihydrochloride
the test compounds
(4a–k,
and donepezil or Do) and the reference
compounds(AAPH)
(ascorbic
acid,
resveratrol,
and
trolox)
were
all
tested
at
final
concentrations
of
10
µ
M
in
assay.
as the oxidant or peroxyl radical ROS generator [19–21]. In our hands, 4.19 µMthe
fluorescein
stock
◦
The
maximal
fluorescence
intensity
was
obtained
by
a
SpectraMax
i3x
microplate
reader
solution was prepared in 75 mM phosphate buffer (pH = 7.4, kept at 4 C), diluted with
the same
equipped with SoftMax Pro 6.5.1 (Molecular Devices, Sunnyvale,
◦ CA, USA) software at an emission

buffer to a concentration of 0.0816 µM, and incubated at 37 C for 15 min before assaying. A fresh
153 mM AAPH solution in the said buffer was prepared, kept on ice, and used for 4 h at the most.
Then, 10 mM solutions of trolox in ethanol, 10 mM solutions of ascorbic acid in water, and 50 mM stock
solutions of test compounds in DMSO were prepared, and each was diluted to 80 µM with ethanol.
Subsequently, 25 µL of each diluted stock solution or 25 µL of ethanol with 0.16% DMSO in case of
control (no test or reference compound) was plated with 150 µL of fluorescein solution, and 25 µL
of the above AAPH solution was added to all wells except those for maximum fluorescence control.
Thus, the test compounds (4a–k, 9a–c, and donepezil or Do) and the reference compounds (ascorbic
acid, resveratrol, and trolox) were all tested at final concentrations of 10 µM in the assay.
The maximal fluorescence intensity was obtained by a SpectraMax i3x microplate reader equipped
Figure
Structures
of the synthesized
(4a–k)
andUSA)
isonipecotates
(9a–c).
that FW wavelength
with SoftMax
Pro1.6.5.1
(Molecular
Devices,hydrazones
Sunnyvale,
CA,
software
at Note
an emission
means Formula Weight and MP denotes Melting Point.
of 520 nm with a preset excitation wavelength of 485 nm. Measurements were taken kinetically
every 22.2.
min
for 60
min Absorbance
at a constant
temperature
of 37 ◦ C. Plates were shaken for 5 s before each
Oxygen
Radical
Capacity
(ORAC) Assay
We needed to screen our compounds for their direct radical scavenging capabilities in both lipid
and aqueous environments. To that end, we utilized the oxygen radical absorbance capacity (ORAC)
assay, which measures peroxyl radical scavenging via hydrogen atom transfer (HAT) or electron
transfer (ET) to the existing or pre-formed radical. Assays details are well reported [17,18]. Briefly,
we utilized known conditions for our assay and 2,2′-azobis(2-amidino-propane) dihydrochloride
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reading.
Measurements
on excitation
multiple wavelength
plates in triplicate
Plates were
wavelength
of 520 nmwere
with arun
preset
of 485 nm.sets.
Measurements
weresealed
taken with
kineticallycover
every to
2 min
for 60 min
at a constantBackground
temperature ofof37the
°C. Plates
were
shaken with
for 5 sappropriate
before
a transparent
prevent
evaporation.
AAPH
solution
each
were run
multiple
plateswas
in triplicate
sets.
Plates
were
sealed
with
amount
of reading.
DMSO, Measurements
ethanol, and buffer,
butonno
fluorescein
taken in
every
plate
and
used
as aa blank
transparent
cover
to
prevent
evaporation.
Background
of
the
AAPH
solution
with
appropriate
for all the wells tested. Percent radical scavenging activity was calculated using the expression:
amount of DMSO, ethanol, and buffer, but no fluorescein was taken in every plate and used as a
[(AUCt − AUCc )/AUCf_max ] × 100%, where AUCt is the net area under the fluorescence curve
blank for all the wells tested. Percent radical scavenging activity was calculated using the expression:
obtained
in the presence of the test/reference compounds, AUCc is the
net area under the fluorescence
[(AUCt − AUCc)/AUCf_max] ×100%, where AUCt is the net area under
the fluorescence curve obtained
curve obtained
for
the
control
sample
that
contained
no
antioxidant
(no
test/reference
compound),
in the presence of the test/reference compounds, AUCc is the net area under
the fluorescence
curve and
AUCf _obtained
under
the fluorescence
obtained for
maximumcompound),
fluorescence
max is the
fornet
thearea
control
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that containedcurve
no antioxidant
(no the
test/reference
andcontrol
sampleAUC
that
contained
andfluorescence
thus had the
maximum
amount
of fluorescein
dye. control
The net area
f_max
is the net no
arearadical
under the
curve
obtained for
the maximum
fluorescence
no radical
and
thusdetermined
had the maximum
of fluorescein
dye. The net area
(AUC)sample
underthat
thecontained
fluorescence
curves
was
using amount
the following
equation:
(AUC) under the fluorescence curves was determined using the following equation:



f 30
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𝑓
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∑f +
∗ ∗ )f
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f0 ismeasured
the measured
fluorescenceintensity
intensity at
at time
thethe
measured
fluorescence
intensity
wherewhere
f 0 is the
fluorescence
time00and
andfi is
fi is
measured
fluorescence
intensity
at time i. The ORAC assay percent radical scavenging activities are reported in Figure 2.
at time i. The ORAC assay percent radical scavenging activities are reported in Figure 2.
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and trolox),
hydrazones
(4a–k),
isonipecotates
and donepezil
(Do)donepezil
determined
the oxygeninradical
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Since Since
the said
compounds
were
Do’sstructural/electronic
structural/electronic
and therefore
the said
compounds
weredesigned
designed to
to mimic
mimic Do’s
and therefore
pharmacologic
behaviors,
molecular
fourteenligands
ligands
were
conducted
against
pharmacologic
behaviors,
moleculardockings
dockings of
of all
all fourteen
were
conducted
against
AChEAChE
crystal
structureof
of AChE
AChE was
derived
fromfrom
the Protein
Data Bank
database
ID: 1EVE)
only. only.
The The
crystal
structure
was
derived
the Protein
Data
Bank(PDB
database
(PDB ID:
[11].
Before
docking,
water
molecules
and
the
embedded
Do
ligand
were
removed
from
the
AChE
1EVE) [11]. Before docking, water molecules and the embedded Do ligand were removed from the
structure.
Non-polar
hydrogens
were added
the protein
using
AutoDock
Tools
(Version Tools
AChEprotein
protein
structure.
Non-polar
hydrogens
weretoadded
to the
protein
using
AutoDock
1.5.6) software and the correct protonation state of each ligand was determined at pH 7.4 using
(Version 1.5.6) software and the correct protonation state of each ligand was determined at pH 7.4
MarvinSketch (Version 17.2.27 ChemAxon, Cambridge, MA, USA) [23]. To create the optimized 3D
using structures,
MarvinSketch
(Version 17.2.27 ChemAxon, Cambridge, MA, USA) [23]. To create the optimized
we used obconformer—a molecular mechanics modeling program based on the force field
3D structures,
we
used
molecular
mechanics
modeling
program
based
on the force
MMFF94 from Openobconformer—a
Babel [24]. Docking
of the ligands
to AChE
was performed
using
AutoDock
field MMFF94
from
Open
Babel
[24].
Docking
of
the
ligands
to
AChE
was
performed
using
AutoDock
Vina (Version 1.1.2) [25]. Flexible ligand conformations were used in all dockings. For search space,
3
Vina (Version
1.1.2)
[25].
Flexible
ligand
conformations
were used
in allsetdockings.
Fororiginally
search space,
a rectangular
box
of size
28.5 × 18.75
× 18.75
Å with its geometrical
center
to that of the
embedded
a rectangular
boxDoofwas
sizeused.
28.5 × 18.75 × 18.75 Å3 with its geometrical center set to that of the originally
different
conformations (1 to 9) with the binding energies sorted from the lowest to highest
embeddedNine
Do was
used.
binding energy were obtained from the molecular docking, and the energies of the representative
Nine different conformations (1 to 9) with the binding energies sorted from the lowest to highest
ligands, Do, 9a, and 9b, are shown in Figure 3. Also, the average and the standard error of each ligand
binding energy were obtained from the molecular docking, and the energies of the representative
ligands, Do, 9a, and 9b, are shown in Figure 3. Also, the average and the standard error of each ligand
are demonstrated for the representative ligands. The average and the minimum binding energies
of all fourteen compounds were evaluated, and their values are represented as the binding energy
differences, i.e., the binding energy of each ligand minus the binding energy of Do; for both, average
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are demonstrated for the representative ligands. The average and the minimum binding energies of

and minimum
energies
are also were
indicated
in Figure
3. It
is clear
that 9a exhibited
the lowest
all fourteen
compounds
evaluated,
and their
values
are represented
as the binding
energydifference
in binding differences,
energy versus
other
compounds.
Figure
4A–C
overlaid
structures
show
the predicted
i.e., the binding energy of each ligand minus the binding energy of Do; for both, average
and
minimum
energies
are
also
indicated
in
Figure
3.
It
is
clear
that
9a
exhibited
the
lowest
difference
conformations of representative ligands Do, 9a, and 9b, respectively. Essentially, nine structures of each
in binding energy versus other compounds. Figure 4A–C overlaid structures show the predicted
ligand are superimposed
and the ones with the lowest binding energies are highlighted in black, pink,
conformations of representative ligands Do, 9a, and 9b, respectively. Essentially, nine structures of
and green, accordingly.
Figures
4D and
respectively
illustrate
the
lowest
structures
each ligand are superimposed
and 4E,
the ones
with the lowest
binding
energies
areenergy
highlighted
in black, of 9a and
9b versus Do
in and
AChE
active
site/gorge.
Notably,
the lowest
energy structure
docked
Do closely
pink,
green,
accordingly.
Figure
4D and Figure
4E, respectively
illustrate of
theour
lowest
energy
structures
9a and 9b crystal
versus Do
in AChE active
site/gorge. Notably,
theSpecifically,
lowest energy we
structure
of
matched that
of theofreported
structure
of embedded
Do [11].
observed
close
our docked Do closely matched that of the reported crystal structure of embedded Do [11].
proximities of the following protein residues with various groups of Do: (1) Trp279 to the indanone
Specifically, we observed close proximities of the following protein residues with various groups of
ring of Do via
π-πTrp279
interactions
at thering
proposed
to theatgorge
of AChE;
(2) PhE330
and Tyr121
Do: (1)
to the indanone
of Do viaentrance
π-π interactions
the proposed
entrance
to the gorge
to the nitrogen
of
the
piperidine
ring
of
Do
via
cation-π
and
hydrogen
bonding,
respectively,
in the
of AChE; (2) PhE330 and Tyr121 to the nitrogen of the piperidine ring of Do via cation-π and
hydrogen
bonding,
respectively,
in
the
middle
of
the
gorge;
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2.4. In Vitro AChE/BuChE Inhibition
To determine compound selectivity, both AChE and BuChE inhibitory studies were undertaken.
The two assays were conducted using modified Ellmann’s procedures [26–29]. Electric eel AChE
(catalog number: C2888-500UN) and equine serum BuChE (catalog number: C4290-1KU) were
purchased from (Sigma-Aldrich, St. Louis, MO, USA). Enzyme aliquots of 6 U/mL were prepared in
20 mM HEPES buffer (Ph = 8.0) containing 0.1% TritonX-100, stored at −20 °C until use, when they
were thawed and diluted 20X with 100 mM phosphate buffer (pH = 8.0). Subsequently, 10 mM Stock
solutions of inhibitors (test compounds, galantamine (Ga) and Do) were prepared in DMSO and then
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To determine compound selectivity, both AChE and BuChE inhibitory studies were undertaken.
The two assays were conducted using modified Ellmann’s procedures [26–29]. Electric eel AChE
(catalog number: C2888-500UN) and equine serum BuChE (catalog number: C4290-1KU) were
purchased from (Sigma-Aldrich, St. Louis, MO, USA). Enzyme aliquots of 6 U/mL were prepared in
20 mM HEPES buffer (Ph = 8.0) containing 0.1% TritonX-100, stored at −20 ◦ C until use, when
they were thawed and diluted 20X with 100 mM phosphate buffer (pH = 8.0). Subsequently,
10 mM Stock solutions of inhibitors (test compounds, galantamine (Ga) and Do) were prepared
in DMSO and then diluted to 0.15 mM through a co-solvent method by adding 145.5 µL of 0.1 M
phosphate buffer (pH = 8.0) and 150 µL of acetonitrile to 4.5 µL of 10 mM inhibitor stock solution.
5,50 -dithio-bis-(2-nitrobenzoic acid) or DTNB, also called Ellman’s reagent, stock solution of 0.4341 mM
in 100 mM phosphate (pH = 8.0 buffer) was also prepared. Finally, depending on the assay,
acetylthiocholine or butyrylthiocholine stock solutions (4.124 mM in 100 mM phosphate buffer,
pH = 8.0) were made. These stock solutions were used in the ensuing enzymatic reactions in 96 wells.
Ultimately, each well comprised a final assay volume of 150 µL and the following ingredients: 0.34 mM
DTNB, 0.02 unit/mL AChE or BuChE, 0.55 mM acetylthiocholine or butyrylthiocholine, and 2 µM
inhibitor (except in the case of the control, which had no inhibitor) for AChE or 10 µM inhibitor (except
in the case of the control, which contained no inhibitor) for BuChE. Assays were also carried out
with a blank solution containing all components except the enzyme and inhibitor so as to account for
non-enzymatic reactions.
Measurements were run on multiple plates, in triplicates. The substrates acetylthiocholine and
butyrylthiocholine were cleaved by their respective enzymes, generating thiol groups detected via their
reaction with the colorimetric Ellman’s reagent, DTNB. Initial rate measurements were performed at
37 ◦ C using a VersaMax microplate reader with SoftMax Pro 5 software (Molecular Devices, Sunnyvale,
CA, USA) and collecting absorbances at 412 nm every 15 s for 15 min. Percent inhibitions of the enzyme
activity due
to the
of test compounds with respect to the control were calculated
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3. and
Results
and Discussion
11 4,5-dimethoxy-2-nitrobenzohydrazideor
or hydrazone
plus
three
1-(1-benzylpiperidinOverall,Overall,
11 4,5-dimethoxy-2-nitrobenzohydrazide
hydrazone
plus
three
1-(1-benzylpiperidin4-yl)ethan-1-one
or
isonipecotate
derivatized
small
molecules
(Figure
1,
FWs
<500)
were
synthesized
4-yl)ethan-1-one or isonipecotate derivatized small molecules (Figure 1, FWs <500) were
synthesized
and preliminarily evaluated at 10 μM for free radical scavenging abilities, and at 2 μM for
and preliminarily evaluated at 10 µM for free radical scavenging abilities, and at 2 µM for cholinesterase
cholinesterase inhibition, using established techniques. Compounds 4a, 4d–g, and 9b potently
inhibition, using established techniques. Compounds 4a, 4d–g, and 9b potently scavenged radicals
scavenged radicals (>30%) in the ORAC assay; that is, they performed at or better than ascorbic acid.
(>30%) inInthe
is, theycomparable
performed
or better
than ascorbic
acid.resveratrol.
In fact, 4a,
4d, and
fact,ORAC
4a, 4d,assay;
and 4gthat
performed
to at
reference
compounds
trolox and
The
ORAC differentiation in antioxidant capability is significant because this assay employs radicals with
practical relevance in living organisms.
In terms of cholinergic activity, most analogs poorly inhibited (<10%) AChE and BuChE. The
exception was isonipecotates 9a and 9c, which modestly inhibited (10–20%) both enzymes. As
expected, the reference compounds (Ga and Do) differentially inhibited AChE (almost 60% for Ga,
and 98% for Do) and BuChE (by about 30% by Ga, and 60% for Do). Despite the low enzyme
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4g performed comparable to reference compounds trolox and resveratrol. The ORAC differentiation in
antioxidant capability is significant because this assay employs radicals with practical relevance in
living organisms.
In terms of cholinergic activity, most analogs poorly inhibited (<10%) AChE and BuChE.
The exception was isonipecotates 9a and 9c, which modestly inhibited (10–20%) both enzymes.
As expected, the reference compounds (Ga and Do) differentially inhibited AChE (almost 60% for Ga,
and 98% for Do) and BuChE (by about 30% by Ga, and 60% for Do). Despite the low enzyme inhibitory
activities, we were encouraged by a finding that a linear correlation existed when calculated binding
free energy (kcal/mol) differences and experimentally derived % AChE binding inhibition differences
were plotted, as illustrated in Figure 6. This correlation was meaningful because it confirmed that
our predictive computational model for AChE binding was on the right path and implied that the
designed compounds yielded useful leads whose cholinergic shortfall could be improved by SAR
(structure activity studies). We now know that π-π stacking may not be the only essential SAR element
for AChE/BuChE inhibition. Rather, a combination of π-π interactions plus H-bonding or polar groups
Sci. Pharm. 2017, 86, 2
8 of 9
may prove
useful.
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good leads with strong antioxidant and minimal AChE inhibition activities. SAR studies and additional
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